THE LEVEL OF Α-SYNUCLEIN IN THE PLASMA AS A BIOMARKER OF PAIN IN PARKINSON'S DISEASE TAKING INTO ACCOUNT THE MOTOR SUBTYPES

Autor: K.A. Tarianyk
Jazyk: English<br />Russian<br />Ukrainian
Rok vydání: 2024
Předmět:
Zdroj: Проблеми екології та медицини, Vol 28, Iss 2, Pp 35-40 (2024)
Druh dokumentu: article
ISSN: 2073-4662
2519-2302
DOI: 10.31718/mep.2024.28.2.05
Popis: Introduction. Parkinson's disease is a chronic progressive neurodegenerative disease characterized by a wide range of motor and non-motor symptoms, among which pain plays a major role. The question arises of the relationship between the concentration of α-synuclein and the level of pain syndrome in Parkinson's disease and the possibility of its use as a biomarker. The aim of the study was to evaluate the relationship between the concentration of α-synuclein in the blood plasma of patients with Parkinson's disease and the level of severity of the pain syndrome, taking into account the motor subtype. Research methods. The study included 64 patients with Parkinson's disease and 30 controls. Parkinson's disease was verified according to the recommendations of the International Society of Movement Disorders and Parkinson's Disease, and the motor subtype was determined according to the Stebin method. The examined patients were divided into 3 groups according to the motor subtype: group 1 (38 people) – patients with a subtype with a predominance of postural instability and gait disorders; group 2 (26 people) – patients with tremor-predominant subtype and mixed subtype; control group (30 people) – conditionally healthy people who did not have damage to the central nervous system. The level of alpha-α-synuclein was measured by enzyme-linked immunosorbent assay in fasting peripheral venous plasma at 6:00 AM. The results. There were no age or gender differences between the groups of patients, as well as the severity of the clinical condition. In patients with Parkinson's disease, a moderately pronounced pain syndrome was found, with no significant differences between patients with different forms of Parkinson's disease. The level of α-synuclein does not differ in different motor subtypes of Parkinson's disease, but significantly exceeds the value of healthy individuals. Conclusions. The concentration of α-synuclein in fasting blood plasma can be considered as a biomarker of the severity of pain syndrome in patients with Parkinson's disease, regardless of the motor subtype.
Databáze: Directory of Open Access Journals
Externí odkaz: